Understanding ependymoma: Current insights and therapeutic advances.

Kenzo Takenaka*

Department of Neurohistology, University of Yamanashi, Yamanashi, Japan

Introduction

Ependymoma, a rare form of primary brain or spinal cord tumor, arises from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord. Though infrequent compared to other brain tumors, its impact can be substantial due to its complexities and the challenges in its treatment [1].

Epidemiology

Ependymoma represent a small percentage of brain tumors, accounting for around 2-3% of all primary brain tumors in both pediatric and adult populations. They can occur at any age but are more frequently diagnosed in children [2].

Etiology and risk factors

The exact cause of ependymoma remains elusive, with no clearly defined risk factors. However, some genetic predispositions or syndromes might increase susceptibility to developing this tumor. These include neurofibromatosis type 2 (NF2) and Li-Fraumeni syndrome, among others [3].

Classification

Ependymoma are categorized based on their location within the central nervous system (CNS) and histological characteristics. Classification involves various grades: Grade I (subependymoma), Grade II (classic ependymoma) and Grade III (anaplastic ependymoma), with varying prognoses and treatment approaches [4].

Pathophysiology and molecular markers

Explore the underlying biology of ependymoma, focusing on molecular markers, genetic mutations, and signaling pathways implicated in tumor development [5].

Clinical presentation

Symptoms of ependymoma can vary widely based on their location within the CNS. Common signs include headaches, nausea, vomiting, seizures, and neurological deficits such as weakness or sensory changes. Diagnosis typically involves imaging studies like MRI or CT scans, followed by histological analysis through biopsy [6].

Treatment modalities

Surgery: Discuss the role of surgery as the primary treatment and the challenges associated with complete resection.

Radiation therapy: Explore the use of radiation in treating ependymoma, including its efficacy and potential side effects.

Chemotherapy: Assess the role of chemotherapy in managing ependymoma, including its limitations and emerging approaches [7].

Challenges in management

The management of ependymoma presents several challenges. Due to its location in critical areas of the CNS and potential for infiltrative growth, complete surgical removal might be difficult. Furthermore, the blood-brain barrier limits the effectiveness of certain chemotherapy agents [8].

Emerging therapies and research

Recent advancements in molecular profiling and understanding tumor biology have opened avenues for targeted therapies. Immunotherapy and novel drug delivery systems are being explored to improve treatment efficacy while minimizing adverse effects. Clinical trials focusing on personalized medicine approaches are underway, offering hope for more tailored treatments [9].

Prognosis and long-term considerations

Prognosis varies significantly depending on factors such as tumor grade, extent of resection, and age at diagnosis. Long-term monitoring is essential due to the potential for tumor recurrence, necessitating regular imaging and clinical follow-ups to detect any signs of recurrence or treatment-related complications [10].

Conclusion

Ependymoma pose significant challenges in diagnosis and management due to their rarity and complexity. While progress in understanding its molecular underpinnings and advancements in treatment strategies offers hope, continued research and collaborative efforts are crucial in improving outcomes and quality of life for individuals affected by this condition. Advances in molecular profiling and targeted therapies offer promising avenues for improved management and prognosis. Multidisciplinary approaches involving surgery, radiation, and evolving systemic therapies are crucial in addressing this condition effectively.

References

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the

***Correspondence to:** Kenzo Takenaka, Department of Neurohistology, University of Yamanashi, Yamanashi, Japan. E-mail: takeken@mail.doshisha.ac.jp

***Received:** 20-Oct-2023, Manuscript No. AAJNNR-23-120555; **Editor assigned:** 23-Oct-2023, Pre QC No. AAJNNR-23-120555(PQ); **Reviewed:** 06-Nov-2023, QC No. AAJNNR-23-120555; **Revised:** 16-Nov-2023, Manuscript No. AAJNNR-23-120555(R); **Published:** 23-Nov-2023, DOI: 10.35841/aajnnr-8.6.180*

***Citation:** Takenaka K. Understanding ependymoma: Current insights and therapeutic advances. J Neurol Neurorehab Res. 2023;8(6):180*

central nervous system: a summary. Acta Neuropathol. 2016;131:803-20.

2. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381-96.
3. Merchant TE, Bendel AE, Sabin ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol. 2019;37(12):974.
4. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465-72.
5. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145-60.
6. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS one. 2008;3(8):3088.
7. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821-31.
8. Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728-43.
9. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer cell. 2011;20(2):143-57.
10. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2(7):395-403.

Citation: *Takenaka K. Understanding ependymoma: Current insights and therapeutic advances. J Neurol Neurorehab Res. 2023;8(6):180*